• Home
  • Stock News
  • Coronavirus Update: WHO says omicron subvariant is not stopping global cases from falling, and U.S. nearing 940,000 COVID deaths

Post: Coronavirus Update: WHO says omicron subvariant is not stopping global cases from falling, and U.S. nearing 940,000 COVID deaths

The World Health Organization said the BA.2 subvariant of the omicron strain of the coronavirus that causes COVID-19 appears to be more transmissible than the original omicron, but is not stopping overall case tallies from declining globally.

In a special statement on the omicron variant, the agency said public health officials should continue to monitor BA.2, which differs from BA.1 in its genetic sequence, including some amino acid differences in the spike protein and other proteins.

While BA.2 is more infectious than the original omicron, the difference is much smaller than the difference between delta and omicron, said the statement. And for now, it appears no more lethal than the original omicron, which has caused many breakthrough infections in vaccinated people and those who have had a booster. But those cases have been mostly mild or asymptomatic, making it a high risk mostly for unvaccinated people.

” Further, although BA.2 sequences are increasing in proportion relative to other Omicron sublineages (BA.1 and BA.1.1), there is still a reported decline in overall cases globally,” said the statement.

The WHO’s weekly epidemiological update is showing that global cases of COVID fell 21% in the week through Feb. 20, while the number of deaths fell by 8% compared to the previous week.

Across the agency’s six regions, more than 12 million cases were recorded and over 67,000 deaths. The Western Pacific Region was the only one to see an increase in weekly cases — of 29%. All others showed cases falling, led by South East Asia, where they fell 37%.

Read also: Ivermectin and hydroxychloroquine more likely to be prescribed in Republican counties, study finds

MarketWatch’s deep dive into ivermectin: ‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data.

The U.S. is averaging about 81,823 cases of COVID a day, down 66% from two weeks ago, according to a New York Times tracker, as the surge of cases caused by omicron continues to decline from its January peak.

The U.S. is averaging 62,464 hospitalizations a day, down 44% from two weeks ago. And deaths are finally starting to fall, down 24% to an average of 1,960 a day.

See also: Why we won’t see herd immunity for COVID-19

New studies offer clues about who may be more susceptible to long Covid, a term for lingering Covid-19 symptoms. WSJ breaks down the science of long Covid and the state of treatment. Illustration: Jacob Reynolds for the Wall Street Journal

Other COVID-19 news you should know about:

• Sanofi


and GlaxoSmithKline


 said their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend to seek regulatory approval for the shot, Dow Jones Newswires reported. The two pharma giants said their vaccine candidate showed efficacy against the virus when used both as primary vaccination and as a booster dose. Phase 3 trials of the shot showed it was 100% effective against severe Covid-19 and hospitalization, and 75% effective against moderate or severe disease, Sanofi and Glaxo said. Final analysis of a booster use of the shot confirmed that it can boost neutralizing antibodies 18- to 30-fold when used after two doses of different available vaccines, the companies said

• Moderna

and life sciences company Thermo Fisher

have entered a long-term agreement to collaborate on large-scale manufacturing of the former’s COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna’s pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine. The expanded agreement will see them offer capacity for other fill-finish services and provide inspection, labeling and final packaging services. 

• Hong Kong parents are being separated from children and babies who test positive for the coronavirus, AFP reported. The move has raised public anger over the lack of readiness for a major outbreak of COVID that is sweeping the city. Hong Kong has been ordered by China to stick to its zero-Covid policy and aim to isolate anyone who tests positive even though the number of daily cases has soared far beyond capacity.

Amid a surge in cases, some countries are handing out second booster shots. In Israel, early data suggest a fourth vaccine dose can increase antibodies against Covid-19, but not enough to prevent infections from Omicron. WSJ explains. Photo composite: Eve Hartley/WSJ

• South Korea has approved the vaccine developed by Pfizer

and German partner BioNTech for children aged 5 to 11, the Associated Press reported. The Korea Disease Control and Prevention Agency reported a record 171,452 new virus cases on Wednesday, nearly a 40-fold increase from levels in mid-January when omicron first emerged as the country’s dominant strain. The 99 new deaths were the highest daily tally since Dec. 31, when the country was grappling with a delta-driven surge that buckled hospital systems.

Here’s what the numbers say

The global tally of confirmed cases of COVID-19 rose above 428.2 million on Thursday, according to data aggregated by Johns Hopkins University, while the death toll climbed above 5.9 million.

The U.S. leads the world with 78.7 million cases and 939,212 deaths.

The Centers for Disease Control and Prevention’s tracker shows that 215 million people living in the U.S. are fully vaccinated, equal to 64.8% of the population. But just 93.2 million are boosted, equal to 43.4% of the vaccinated population. 

Add Your Heading Text Here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Market Insiders